FlandersBio on Twitter

Follow us on Twitter



in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

VIB-UGent announces partnership with Umeå Plant Science Centre and SweTree Technologies to help advance forestry plantations


VIB-UGent today announced it has entered into a partnership with the Swedish SweTree Technologies and Umeå Plant Science Centre (UPSC) to accelerate research on tree value and productivity. The study results will be published in leading scientific journals. read more

Athersys Subsidiary and Leading Animal Health Company Enter Into Research and Option Agreement for Cell Therapy


Athersys, Inc. (NASDAQ:ATHX) announced today that through its Belgian subsidiary, ReGenesys BVBA (ReGenesys), it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area. Additional details were not disclosed. read more

New insights in genetic defect allow prevention of fatal illnesses in children


A team of scientists led by prof. Adrian Liston (VIB–KU Leuven) and prof. Isabelle Meyts (UZ Leuven – KU Leuven) were able to characterize a new genetic immunodeficiency resulting from a mutation in a gene named STAT2. This mutation causes patients to be extremely vulnerable to normally mild childhood illnesses such as rotavirus and enterovirus. Prof. Liston’s comprehensive analysis of the genetic defect allows clinicians to provide children with the proper therapies before illnesses prove fatal. The findings of the research have been published in the Journal of Allergy and Clinical Immunology. read more

OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors


OCTIMET Oncology NV (OCTIMET), has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the development of a clinically de-risked MET kinase inhibitor, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers. read more

UgenTec in zee met Australische antibiotica-testontwikkelaar


UgenTec, de Limburgse startup die DNA analyse automatiseert met behulp van artificiële intelligentie, heeft een software plugin opgeleverd voor SpeeDx, een Australisch diagnostisch bedrijf dat testen heeft om antibiotica resistentie snel op te sporen. read more

Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive


Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/238,310 a patent which covers the use of Estetrol (E4) as an emergency contraceptive. read more

Ablynx Announces Warrant Excercise


Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 154,342 common shares have been issued by the Company in exchange for €1,011,939.05 as the result of the exercise of warrants. read more

MDxHealth Announces Horizon Blue Cross Blue Shield of New Jersey Issues Positive Coverage Policy on ConfirmMDx


MDxHealth SA (Euronext: MDXH.BR) today announced that Horizon Blue Cross Blue Shield (Horizon BCBS) of New Jersey has issued a positive medical policy for the ConfirmMDx® for Prostate Cancer test. read more

Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer


Galapagos NV (Euronext & NASDAQ: GLPG) announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical Officer, beginning on 1 March 2017. read more

VIB-expo Science meets Life tot 12 februari in Leuven Biotechtour toont belang van biotechsector voor onze maatschappij


Met de rondreizende expo Science meets Life zet VIB het belang van biotechonderzoek in de kijker. VIB bestaat immers 20 jaar en wil de Leuvense bevolking laten kennismaken met wat 20 jaar gerichte investeringen in biotechonderzoek hebben opgebracht. De tentoonstelling loopt vanaf 16 januari op verschillende locaties in de stad Leuven. Aftrap werd gegeven in Health House, een nieuw interactief exhibitie-concept voor business en research communities dat op een unieke manier de toenemende impact van nieuwe technologie op gezondheid en zorg in beeld brengt. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top